ID   HEp-2
AC   CVCL_1906
SY   Hep-2; HEP-2; Hep2 (HeLa derivative); HEp-2/HeLa; Hep 2; Hep2; HEp2; HEP2; H.Ep.-2; H.Ep. #2; H.Ep. No. 2; Hep II; Human Epidermoid carcinoma #2; Human Epithelioma-2
DR   BTO; BTO:0000976
DR   CLO; CLO_0003706
DR   CLO; CLO_0003707
DR   CLO; CLO_0050927
DR   EFO; EFO_0006438
DR   CLDB; cl1646
DR   CLDB; cl1647
DR   CLDB; cl1649
DR   CLDB; cl1650
DR   CLDB; cl1653
DR   CLDB; cl1654
DR   CLDB; cl1655
DR   AddexBio; C0050001/4983
DR   ArrayExpress; E-MTAB-2706
DR   ATCC; CCL-23
DR   BCRC; 60042
DR   BCRJ; 0101
DR   BioSample; SAMN03151706
DR   CCLV; CCLV-RIE 0141
DR   CCRID; 1101HUM-PUMC000068
DR   CCRID; 4201PAT-CCTCC00214
DR   CCTCC; GDC0004
DR   Cell_Model_Passport; SIDM01208
DR   ChEMBL-Cells; CHEMBL3307694
DR   ChEMBL-Targets; CHEMBL614735
DR   CLS; 300397
DR   Cosmic; 1339928
DR   Cosmic; 1530739
DR   Cosmic; 1969495
DR   Cosmic; 2301559
DR   ECACC; 86030501
DR   EGA; EGAS00001000610
DR   GEO; GSM1374529
DR   GEO; GSM1374530
DR   IZSLER; BS TCL 23
DR   KCLB; 10023
DR   NCBI_Iran; C144
DR   PharmacoDB; HEp2_540_2019
DR   PRIDE; PXD006201
DR   PRIDE; PXD013072
DR   PRIDE; PXD014913
DR   PRIDE; PXD031726
DR   PubChem_Cell_line; CVCL_1906
DR   RCB; RCB1889
DR   TKG; TKG 0403
DR   TOKU-E; 1442
DR   Wikidata; Q16554737
RX   CelloPub=CLPUB00484;
RX   DOI=10.1007/978-1-4757-1647-4_13;
RX   DOI=10.1007/BF02618370;
RX   DOI=10.11418/jtca1981.17.3_95;
RX   PubMed=566722;
RX   PubMed=1246601;
RX   PubMed=3180844;
RX   PubMed=4203458;
RX   PubMed=4864103;
RX   PubMed=5641128;
RX   PubMed=5668122;
RX   PubMed=6988327;
RX   PubMed=8397027;
RX   PubMed=11416159;
RX   PubMed=13209540;
RX   PubMed=13261081;
RX   PubMed=14185313;
RX   PubMed=17254797;
RX   PubMed=19450234;
RX   PubMed=19941903;
RX   PubMed=20143388;
RX   PubMed=23925245;
RX   PubMed=25485619;
RX   PubMed=26589293;
RX   PubMed=29483928;
RX   PubMed=29967540;
RX   PubMed=31105993;
RX   PubMed=33389257;
RX   PubMed=34024160;
RX   PubMed=34697958;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-204.html
WW   https://en.vircell.com/products/hep-2-cell-line/
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
WW   https://es.wikipedia.org/wiki/C%C3%A9lulas_HEp-2
CC   Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=20143388). Originally thought to originate from a 56 year old male patient with a laryngeal carcinoma.
CC   Part of: KuDOS 95 cell line panel.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00007.
CC   Population: African American.
CC   Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257).
CC   HLA typing: A*68:02,68:02; B*15:03,15:03; C*12:03,12:03 (PubMed=26589293).
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Omics: Genome sequenced (low read coverage).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Ubiquitination analysis by proteomics.
CC   Discontinued: BCRC; 60042; true.
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; KCLB; PubMed=11416159; PubMed=17254797; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 12 (RCB)
ST   D13S317: 12,13.3 (AddexBio; ATCC; CCRID; CLS; KCLB; TKG)
ST   D13S317: 12,14 (PubMed=17254797)
ST   D16S539: 9,10
ST   D18S51: 15 (PubMed=17254797)
ST   D18S51: 16 (CCRID; CLS; PubMed=11416159)
ST   D19S433: 13,14
ST   D21S11: 26,27 (PubMed=17254797)
ST   D21S11: 27,28 (CCRID; CLS; PubMed=11416159)
ST   D2S1338: 17
ST   D3S1358: 15,18
ST   D5S818: 11,12
ST   D7S820: 8,12
ST   D8S1179: 12,13
ST   FGA: 18,21
ST   Penta D: 8,15
ST   Penta E: 7,17
ST   TH01: 7
ST   TPOX: 8,12
ST   vWA: 16,18
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 40
//
RX   CelloPub=CLPUB00484;
RA   Xu Z.-H., Sun W.-W., Hang J.-B., Gao B.-L., Hu J.-A.;
RT   "RNA-seq identified a novel functional MET fusion in head and neck
RT   cancer 5-8F cell line.";
RL   Int. J. Clin. Exp. Pathol. 9:8308-8317(2016).
//
RX   DOI=10.1007/978-1-4757-1647-4_13;
RA   Biedler J.L.;
RT   "Chromosome abnormalities in human tumor cells in culture.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York (1975).
//
RX   DOI=10.1007/BF02618370;
RA   Stulberg C.S., Coriell L.L., Kniazeff A.J., Shannon J.E.;
RT   "The animal cell culture collection.";
RL   In Vitro 5:1-16(1970).
//
RX   DOI=10.11418/jtca1981.17.3_95;
RA   Tsuboi I., Taguchi M., Kenmotsu M., Ban F., Machida K., Inagaki K.,
RA   Ishi A., Tazawa T.;
RT   "A new substrain derived from HEp-2 for the detection of anti-nuclear
RT   antibodies.";
RL   Tissue Cult. Res. Commun. 17:95-100(1998).
//
RX   PubMed=566722; DOI=10.1007/BF02616110;
RA   Lavappa K.S.;
RT   "Survey of ATCC stocks of human cell lines for HeLa contamination.";
RL   In Vitro 14:469-475(1978).
//
RX   PubMed=1246601; DOI=10.1126/science.1246601;
RA   Nelson-Rees W.A., Flandermeyer R.R.;
RT   "HeLa cultures defined.";
RL   Science 191:96-98(1976).
//
RX   PubMed=3180844; DOI=10.1159/000132579;
RA   Chen T.-R.;
RT   "Re-evaluation of HeLa, HeLa S3, and HEp-2 karyotypes.";
RL   Cytogenet. Cell Genet. 48:19-24(1988).
//
RX   PubMed=4203458;
RA   Petricciani J.C., Wallace R.E., McCoy D.W.;
RT   "A comparison of three in vivo assays for cell tumorigenicity.";
RL   Cancer Res. 34:105-108(1974).
//
RX   PubMed=4864103;
RA   Gartler S.M.;
RT   "Genetic markers as tracers in cell culture.";
RL   Natl. Cancer Inst. Monogr. 26:167-195(1967).
//
RX   PubMed=5641128; DOI=10.1038/217750a0;
RA   Gartler S.M.;
RT   "Apparent Hela cell contamination of human heteroploid cell lines.";
RL   Nature 217:750-751(1968).
//
RX   PubMed=5668122; DOI=10.3181/00379727-128-33119;
RA   Peterson W.D. Jr., Stulberg C.S., Swanborg N.K., Robinson A.R.;
RT   "Glucose-6-phosphate dehydrogenase isoenzymes in human cell cultures
RT   determined by sucrose-agar gel and cellulose acetate zymograms.";
RL   Proc. Soc. Exp. Biol. Med. 128:772-776(1968).
//
RX   PubMed=6988327; DOI=10.1007/BF02831503;
RA   O'Brien S.J., Shannon J.E., Gail M.H.;
RT   "A molecular approach to the identification and individualization of
RT   human and animal cells in culture: isozyme and allozyme genetic
RT   signatures.";
RL   In Vitro 16:119-135(1980).
//
RX   PubMed=8397027;
RA   Ogura H., Yoshinouchi M., Kudo T., Imura M., Fujiwara T., Yabe Y.;
RT   "Human papillomavirus type 18 DNA in so-called HEP-2, KB and FL
RT   cells -- further evidence that these cells are HeLa cell derivatives.";
RL   Cell. Mol. Biol. 39:463-467(1993).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=13209540;
RA   Toolan H.W.;
RT   "Transplantable human neoplasms maintained in cortisone-treated
RT   laboratory animals: H.S. No. 1; H.Ep. No. 1; H.Ep. No. 2; H.Ep. No. 3;
RT   and H.Emb.Rh. No. 1.";
RL   Cancer Res. 14:660-666(1954).
//
RX   PubMed=13261081;
RA   Moore A.E., Sabachewsky L., Toolan H.W.;
RT   "Culture characteristics of four permanent lines of human cancer
RT   cells.";
RL   Cancer Res. 15:598-602(1955).
//
RX   PubMed=14185313; DOI=10.1126/science.146.3641.241;
RG   Cell Culture Collection Committee;
RT   "Animal cell strains. The Cell Culture Collection Committee has
RT   assembled and certified 23 strains of animal cells.";
RL   Science 146:241-243(1964).
//
RX   PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001;
RA   Azari S., Ahmadi N., Tehrani M.J., Shokri F.;
RT   "Profiling and authentication of human cell lines using short tandem
RT   repeat (STR) loci: report from the National Cell Bank of Iran.";
RL   Biologicals 35:195-202(2007).
//
RX   PubMed=19450234; DOI=10.2144/000113089;
RA   Rahbari R., Sheahan T., Modes V., Collier P., Macfarlane C.M.,
RA   Badge R.M.;
RT   "A novel L1 retrotransposon marker for HeLa cell line
RT   identification.";
RL   BioTechniques 46:277-284(2009).
//
RX   PubMed=19941903; DOI=10.1016/j.jviromet.2009.11.022;
RA   Karger A., Bettin B., Lenk M., Mettenleiter T.C.;
RT   "Rapid characterisation of cell cultures by matrix-assisted laser
RT   desorption/ionisation mass spectrometric typing.";
RL   J. Virol. Methods 164:116-121(2010).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=23925245; DOI=10.1038/nature12064;
RA   Adey A., Burton J.N., Kitzman J.O., Hiatt J.B., Lewis A.P.,
RA   Martin B.K., Qiu R.-L., Lee C., Shendure J.;
RT   "The haplotype-resolved genome and epigenome of the aneuploid HeLa
RT   cancer cell line.";
RL   Nature 500:207-211(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=29483928; DOI=10.1186/s11658-017-0067-8;
RA   Li G.-D., Hu X.-L., Sun L., Li X., Li J.-F., Li T.-L., Zhang X.-H.;
RT   "C-fos upregulates P-glycoprotein, contributing to the development of
RT   multidrug resistance in HEp-2 laryngeal cancer cells with VCR-induced
RT   resistance.";
RL   Cell. Mol. Biol. Lett. 23:6.1-6.12(2018).
//
RX   PubMed=29967540; DOI=10.1038/s41594-018-0084-y;
RA   Akimov V., Barrio-Hernandez I., Hansen S.V.F., Hallenborg P.,
RA   Pedersen A.-K., Bekker-Jensen D.B., Puglia M., Christensen S.D.K.,
RA   Vanselow J.T., Nielsen M.M., Kratchmarova I., Kelstrup C.D.,
RA   Olsen J.V., Blagoev B.;
RT   "UbiSite approach for comprehensive mapping of lysine and N-terminal
RT   ubiquitination sites.";
RL   Nat. Struct. Mol. Biol. 25:631-640(2018).
//
RX   PubMed=31105993;
RA   Gorphe P.;
RT   "A comprehensive review of Hep-2 cell line in translational research
RT   for laryngeal cancer.";
RL   Am. J. Cancer Res. 9:644-649(2019).
//
RX   PubMed=33389257; DOI=10.1007/s10096-020-04106-0;
RA   Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.;
RT   "Culture of SARS-CoV-2 in a panel of laboratory cell lines,
RT   permissivity, and differences in growth profile.";
RL   Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021).
//
RX   PubMed=34024160; DOI=10.2144/btn-2020-0162;
RA   Fusi M., Dotti S.;
RT   "Adaptation of the HEp-2 cell line to totally animal-free culture
RT   systems and real-time analysis of cell growth.";
RL   BioTechniques 70:319-326(2021).
//
RX   PubMed=34697958; DOI=10.1177/24725552211051963;
RA   Korch C.T., Capes-Davis A.;
RT   "The extensive and expensive impacts of HEp-2 [HeLa], intestine 407
RT   [HeLa], and other false cell lines in journal publications.";
RL   SLAS Discov. 26:1268-1279(2021).
//